Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies
Open Access
- 26 June 2026
- journal article
- review article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2689287
Abstract
Inflammation is a finely tuned host defense mechanism whose perpetual activation is a driver, promoter, and supporter of carcinogenesis. Key mediators of chronic inflammatory processes, viz. NF-kB, JAK-STAT, inflammasomes, reactive oxygen species (ROS), and cytokine network, if left unanswered, foster the tumour-supportive environment. Within the tumour microenvironment (TME), inflammatory cells, in combination with stromal and cancerous cells, modulate these pathways and regulate critical tumour hallmarks. Therefore, efforts have been made to understand and tackle the interface between the inflammation-cancer axis, but therapeutic outcomes remain limited. In this context, integrating systems-level biological insights with precision-driven medicinal chemistry may pave the way towards next-generation anti-inflammatory chemotherapeutics. The current review underlines the critical involvement of inflammation in cancer development by providing a comprehensive overview of key molecular pathways. A special emphasis was placed on understanding the medicinal chemistry campaign over the last 5 years for the development of inflammation-targeting small-molecule therapeutics in cancer.Keywords
Funding Information
- MacKay Medical Hospital (MMH-115-047)
- National Science and Technology Council (114-2811-B-715-004)
- MacKay Medical University (MMU-RD-112-2A-P003)
This publication has 426 references indexed in Scilit:
- As Based upon Physiological and Pathological HistologyNutrition Reviews, 2009
- NF-κB-Inducing Kinase Regulates the Processing of NF-κB2 p100Molecular Cell, 2001
- Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines.2000
- TNF in the Inflammatory Response1999
- Meloxicam inhibits the growth of colorectal cancer cellsCarcinogenesis, 1998
- Cyclooxygenase in biology and diseaseThe FASEB Journal, 1998
- Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cellsNature, 1996
- Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemopreventionJournal of Cellular Biochemistry, 1992
- A primary determinant for lipoxygenase positional specificityNature, 1991
- Regulation of the immune response by prostaglandinsJournal of Clinical Immunology, 1983